The kymriah market research report is one of a series of new reports that provides kymriah market statistics, including the kymriah industry global market size, regional shares, competitors with the kymriah market share, detailed kymriah market segments, market trends, and opportunities, and any further data you may need to thrive in the kymriah industry. This kymriah market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the increasing number of clinical trials, growing demand for personalized and targeted therapies, rising rate of people being diagnosed, growing investment in biotech, and increasing demand for effective treatment. Major trends in the forecast period include technological advancements in personalized medicine, artificial intelligence (AI) in CAR T-cell therapy, advances in manufacturing, ongoing research into optimizing the efficacy, demand for combination therapies.
The increasing prevalence of hematological cancer is expected to drive the growth of the kymriah market in the future. Hematological cancer encompasses cancers affecting the blood, bone marrow, lymph nodes, and lymphatic system. The rise in these cancers is linked to factors such as an aging population, genetic predispositions, immune system disorders, and lifestyle influences. Kymriah is utilized in the treatment of hematological cancers, specifically certain types of leukemia and lymphoma, by leveraging CAR-T cell therapy to target and destroy cancer cells. For example, in September 2024, the Leukemia & Lymphoma Society (LLS), a US-based charitable organization focused on fighting blood cancers worldwide, reported that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every 3 minutes, with an estimated 187,740 diagnoses of these cancers in 2024. Consequently, the rising prevalence of hematological cancers is driving the growth of the kymriah market.
The growing demand for personalized therapies is another major factor fueling the kymriah market's expansion. Personalized therapies are tailored medical treatments designed to align with an individual's genetic, environmental, and lifestyle characteristics, enhancing their effectiveness and minimizing side effects. The rising demand for these therapies can be attributed to advancements in genetic research, improved understanding of diseases at the molecular level, and enhanced diagnostic tools. Kymriah is particularly advantageous for personalized therapies as it uses a patient's immune cells to target and destroy specific cancer cells, offering a highly customized treatment approach. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. As a result, the growing demand for personalized therapies is propelling the growth of the kymriah market.
A key trend in the kymriah market is the focus on advancing CAR-T cell therapies to improve treatment efficacy and expand the eligible patient population for various hematological cancers. CAR-T cell therapies involve genetically modifying a patient's T cells to express chimeric antigen receptors (CAR), enabling them to detect and eliminate cancer cells, particularly in certain leukemias and lymphomas. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Kymriah (tisagenlecleucel) to treat adult patients with relapsed or refractory follicular lymphoma after undergoing two or more lines of systemic therapy. Kymriah has shown durable results, with 86% of patients responding positively and 68% achieving complete remission. Its ability to provide lasting outcomes, particularly in high-risk patients, sets it apart from other treatments. Notably, Kymriah remains the only CAR-T cell therapy approved for both adult and pediatric patients across multiple indications.
The key company operating in the kymriah market is Novartis AG.
North America was the largest region in the kymriah market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kymriah report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the kymriah market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kymriah is a CAR-T cell therapy designed to modify a patient's T cells to specifically target and attack cancer cells. It is used to treat certain blood cancers by extracting, engineering, and reinfusing T cells that are programmed to recognize cancer-specific markers. This groundbreaking treatment has shown remarkable efficacy in patients with cancers resistant to conventional therapies, offering a potentially life-saving solution.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of kymriah formulations include injectable formulations (intravenous) and customized patient-specific formulations. Injectable intravenous formulations deliver medication directly into the vein, ensuring precise, rapid, and controlled treatment, making them suitable for various conditions. Kymriah is indicated for the treatment of B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and other conditions. It is used across diverse patient demographics, including pediatric, adult, and geriatric populations. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Kymriah is utilized by a range of end users, such as hospitals, oncology clinics, hematology treatment centers, and research institutions.
The kymriah market consists of sales of leukapheresis kits, infusion kits, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the increasing number of clinical trials, growing demand for personalized and targeted therapies, rising rate of people being diagnosed, growing investment in biotech, and increasing demand for effective treatment. Major trends in the forecast period include technological advancements in personalized medicine, artificial intelligence (AI) in CAR T-cell therapy, advances in manufacturing, ongoing research into optimizing the efficacy, demand for combination therapies.
The increasing prevalence of hematological cancer is expected to drive the growth of the kymriah market in the future. Hematological cancer encompasses cancers affecting the blood, bone marrow, lymph nodes, and lymphatic system. The rise in these cancers is linked to factors such as an aging population, genetic predispositions, immune system disorders, and lifestyle influences. Kymriah is utilized in the treatment of hematological cancers, specifically certain types of leukemia and lymphoma, by leveraging CAR-T cell therapy to target and destroy cancer cells. For example, in September 2024, the Leukemia & Lymphoma Society (LLS), a US-based charitable organization focused on fighting blood cancers worldwide, reported that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every 3 minutes, with an estimated 187,740 diagnoses of these cancers in 2024. Consequently, the rising prevalence of hematological cancers is driving the growth of the kymriah market.
The growing demand for personalized therapies is another major factor fueling the kymriah market's expansion. Personalized therapies are tailored medical treatments designed to align with an individual's genetic, environmental, and lifestyle characteristics, enhancing their effectiveness and minimizing side effects. The rising demand for these therapies can be attributed to advancements in genetic research, improved understanding of diseases at the molecular level, and enhanced diagnostic tools. Kymriah is particularly advantageous for personalized therapies as it uses a patient's immune cells to target and destroy specific cancer cells, offering a highly customized treatment approach. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. As a result, the growing demand for personalized therapies is propelling the growth of the kymriah market.
A key trend in the kymriah market is the focus on advancing CAR-T cell therapies to improve treatment efficacy and expand the eligible patient population for various hematological cancers. CAR-T cell therapies involve genetically modifying a patient's T cells to express chimeric antigen receptors (CAR), enabling them to detect and eliminate cancer cells, particularly in certain leukemias and lymphomas. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Kymriah (tisagenlecleucel) to treat adult patients with relapsed or refractory follicular lymphoma after undergoing two or more lines of systemic therapy. Kymriah has shown durable results, with 86% of patients responding positively and 68% achieving complete remission. Its ability to provide lasting outcomes, particularly in high-risk patients, sets it apart from other treatments. Notably, Kymriah remains the only CAR-T cell therapy approved for both adult and pediatric patients across multiple indications.
The key company operating in the kymriah market is Novartis AG.
North America was the largest region in the kymriah market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kymriah report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the kymriah market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kymriah is a CAR-T cell therapy designed to modify a patient's T cells to specifically target and attack cancer cells. It is used to treat certain blood cancers by extracting, engineering, and reinfusing T cells that are programmed to recognize cancer-specific markers. This groundbreaking treatment has shown remarkable efficacy in patients with cancers resistant to conventional therapies, offering a potentially life-saving solution.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of kymriah formulations include injectable formulations (intravenous) and customized patient-specific formulations. Injectable intravenous formulations deliver medication directly into the vein, ensuring precise, rapid, and controlled treatment, making them suitable for various conditions. Kymriah is indicated for the treatment of B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and other conditions. It is used across diverse patient demographics, including pediatric, adult, and geriatric populations. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Kymriah is utilized by a range of end users, such as hospitals, oncology clinics, hematology treatment centers, and research institutions.
The kymriah market consists of sales of leukapheresis kits, infusion kits, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Kymriah Market Characteristics4. Kymriah Market Trends And Strategies5. Kymriah Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Kymriah Pricing Analysis & Forecasts30. Global Kymriah Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Kymriah Market32. Recent Developments In The Kymriah Market
3. Kymriah Market Biologic Drug Characteristics
6. Global Kymriah Growth Analysis And Strategic Analysis Framework
8. Kymriah Market Segmentation
9. Global Kymriah Epidemiology Of Clinical Indications
10. Kymriah Market Regional And Country Analysis
11. Asia-Pacific Kymriah Market
12. China Kymriah Market
13. India Kymriah Market
14. Japan Kymriah Market
15. Australia Kymriah Market
16. South Korea Kymriah Market
17. Western Europe Kymriah Market
18. UK Kymriah Market
19. Germany Kymriah Market
20. France Kymriah Market
21. Eastern Europe Kymriah Market
22. North America Kymriah Market
23. USA Kymriah Market
24. Canada Kymriah Market
25. South America Kymriah Market
26. Middle East Kymriah Market
27. Africa Kymriah Market
28. Kymriah Market Competitive Landscape And Company Profiles
29. Global Kymriah Market Pipeline Analysis
33. Kymriah Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Kymriah Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on kymriah market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kymriah ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kymriah market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Injectable Formulation (Intravenous); Customized Patient-Specific Formulations2) By Indication: Treatment Of B-cell Acute Lymphoblastic Leukemia; Treatment Of Diffuse Large B-cell Lymphoma; Treatment Of Follicular Lymphoma; Other Potential Indications
3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients
4) By Distribution Channel: Direct Sales; Wholesalers And Distributors; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Oncology Clinics; Hematology Treatment Centers; Research Institutions
Key Companies Profiled:Novartis AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
